Capstone Therapeutics (CAPS) Competitors

$0.37 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-3.51%)

As of 05/22/2026 07:59 PM Eastern

CAPS vs. NAII, ZIVO, QNCX, COCP, and NCEL

Should you buy Capstone Therapeutics stock or one of its competitors? MarketBeat compares Capstone Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capstone Therapeutics include Natural Alternatives International (NAII), ZIVO Bioscience (ZIVO), Quince Therapeutics (QNCX), Cocrystal Pharma (COCP), and NLS Pharmaceutics (NCEL). These companies are all part of the "pharmaceutical products" industry.

How does Capstone Therapeutics compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Natural Alternatives International has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market.

In the previous week, Capstone Therapeutics had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 4 mentions for Capstone Therapeutics and 2 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of -0.05 beat Capstone Therapeutics' score of -0.75 indicating that Natural Alternatives International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capstone Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Natural Alternatives International has a net margin of -10.13% compared to Capstone Therapeutics' net margin of -41.26%. Natural Alternatives International's return on equity of -12.21% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Natural Alternatives International has higher revenue and earnings than Capstone Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A

Summary

Natural Alternatives International beats Capstone Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Capstone Therapeutics compare to ZIVO Bioscience?

Capstone Therapeutics (NASDAQ:CAPS) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

ZIVO Bioscience has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. ZIVO Bioscience's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Capstone Therapeutics has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Capstone Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.75 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Negative
ZIVO Bioscience	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Capstone Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A
ZIVO Bioscience	$15.85K	1,075.20	-$7.78M	-$1.71	N/A

Summary

ZIVO Bioscience beats Capstone Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Capstone Therapeutics compare to Quince Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Capstone Therapeutics had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Capstone Therapeutics and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.08 beat Capstone Therapeutics' score of -0.75 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capstone Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Capstone Therapeutics has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Quince Therapeutics has a consensus price target of $65.00, suggesting a potential upside of 5,809.09%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Quince Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
Quince Therapeutics	N/A	-372.88%	-67.99%

Capstone Therapeutics has higher revenue and earnings than Quince Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 20.3% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Capstone Therapeutics and Quince Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Capstone Therapeutics compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Cocrystal Pharma has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 421.74%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Cocrystal Pharma is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 28.1% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cocrystal Pharma has higher earnings, but lower revenue than Capstone Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A

In the previous week, Capstone Therapeutics had 4 more articles in the media than Cocrystal Pharma. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.75 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Capstone Therapeutics	Negative

Cocrystal Pharma has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the broader market.

Summary

Cocrystal Pharma beats Capstone Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Capstone Therapeutics compare to NLS Pharmaceutics?

Capstone Therapeutics (NASDAQ:CAPS) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

NLS Pharmaceutics has lower revenue, but higher earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.10	-$21.23M	-$3.37	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Capstone Therapeutics has a beta of -1.52, suggesting that its share price is 252% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Capstone Therapeutics had 4 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.75 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Negative
NLS Pharmaceutics	Neutral

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NLS Pharmaceutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. NLS Pharmaceutics' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

NLS Pharmaceutics beats Capstone Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPS vs. The Competition

Export

Metric	Capstone Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.71M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.11	18.74	21.00	25.66
Price / Sales	0.10	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.42	7.09	10.41	7.14
Net Income	-$21.23M	$24.45M	$3.57B	$335.98M
7 Day Performance	22.21%	6.38%	6.40%	4.11%
1 Month Performance	-11.94%	2.43%	3.54%	2.52%
1 Year Performance	-80.77%	62.98%	34.14%	35.04%

Capstone Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPS Capstone Therapeutics	0.5675 of 5 stars	$0.37 flat	N/A	-80.8%	$4.71M	$48.11M	N/A	38	Earnings Report Upcoming Earnings Gap Down
NAII Natural Alternatives International	1.416 of 5 stars	$2.80 +5.1%	N/A	-23.9%	$17.27M	$129.86M	N/A	290	Gap Down
ZIVO ZIVO Bioscience	N/A	$4.06 +10.0%	N/A	N/A	$16.86M	$15.85K	N/A	10	Gap Up
QNCX Quince Therapeutics	2.1363 of 5 stars	$1.03 -10.9%	$65.00 +6,241.5%	-90.1%	$16.71M	N/A	N/A	60	Gap Down High Trading Volume
COCP Cocrystal Pharma	1.9885 of 5 stars	$1.18 -1.6%	$6.00 +408.0%	-21.2%	$16.53M	N/A	N/A	10	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capstone Therapeutics (CAPS) Competitors

CAPS vs. NAII, ZIVO, QNCX, COCP, and NCEL

How does Capstone Therapeutics compare to Natural Alternatives International?

Summary

How does Capstone Therapeutics compare to ZIVO Bioscience?

Summary

How does Capstone Therapeutics compare to Quince Therapeutics?

Summary

How does Capstone Therapeutics compare to Cocrystal Pharma?

Summary

How does Capstone Therapeutics compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capstone Therapeutics (CAPS) Competitors

CAPS vs. NAII, ZIVO, QNCX, COCP, and NCEL

How does Capstone Therapeutics compare to Natural Alternatives International?

Do analysts recommend NAII or CAPS?

Do institutionals & insiders believe in NAII or CAPS?

Which has more risk and volatility, NAII or CAPS?

Does the media prefer NAII or CAPS?

Is NAII or CAPS more profitable?

Which has higher earnings & valuation, NAII or CAPS?

Summary

How does Capstone Therapeutics compare to ZIVO Bioscience?

Is CAPS or ZIVO more profitable?

Which has more risk & volatility, CAPS or ZIVO?

Do insiders & institutionals believe in CAPS or ZIVO?

Does the media favor CAPS or ZIVO?

Do analysts recommend CAPS or ZIVO?

Which has preferable earnings and valuation, CAPS or ZIVO?

Summary

How does Capstone Therapeutics compare to Quince Therapeutics?

Does the media favor CAPS or QNCX?

Which has more risk & volatility, CAPS or QNCX?

Do analysts prefer CAPS or QNCX?

Is CAPS or QNCX more profitable?

Which has stronger earnings & valuation, CAPS or QNCX?

Do institutionals and insiders have more ownership in CAPS or QNCX?

Summary

How does Capstone Therapeutics compare to Cocrystal Pharma?

Is COCP or CAPS more profitable?

Do analysts rate COCP or CAPS?

Do institutionals and insiders believe in COCP or CAPS?

Which has preferable valuation and earnings, COCP or CAPS?

Does the media refer more to COCP or CAPS?

Which has more risk and volatility, COCP or CAPS?

Summary

How does Capstone Therapeutics compare to NLS Pharmaceutics?

Which has higher earnings and valuation, CAPS or NCEL?

Which has more volatility and risk, CAPS or NCEL?

Do analysts rate CAPS or NCEL?

Does the media favor CAPS or NCEL?

Do institutionals and insiders hold more shares of CAPS or NCEL?

Is CAPS or NCEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools